Tumor News and Research

RSS

"Self-fitting" material precisely fills bone defects and acts as scaffold for new bone growth

Injuries, birth defects (such as cleft palates) or surgery to remove a tumor can create gaps in bone that are too large to heal naturally. And when they occur in the head, face or jaw, these bone defects can dramatically alter a person's appearance.

13 Aug 2014

MRI technology improves prostate cancer diagnosis

Oncologists at UC San Diego Moores Cancer Center are the first in San Diego to meld magnetic resonance imaging (MRI) technology with a traditional ultrasound prostate exam to create a three-dimensional map of the prostate that allows physicians to view growths that were previously undetectable.

13 Aug 2014

Identifying epigenetic markers in cancer cells could improve patient treatment

Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer.

13 Aug 2014

Imaging system rapidly detects molecular marker in brain gliomas, enables removal of tumor

During tumor surgery, surgeons work to remove tumor tissue without damaging surrounding healthy tissue.

13 Aug 2014

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

12 Aug 2014

Prominent scientists to deliver scientific presentations at ACS meeting

The Kavli Foundation Lecture series today features two prominent scientists: one in the booming area of ionic liquids, the other in medical materials.

12 Aug 2014

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor.

12 Aug 2014

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor.

12 Aug 2014

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable."

12 Aug 2014

Bee, snake, scorpion venom could form basis of new generation of cancer-fighting drugs

Bee, snake or scorpion venom could form the basis of a new generation of cancer-fighting drugs, scientists will report here today.

12 Aug 2014

Researchers discover how arginine starvation specifically kills cancer cells

Researchers at UC Davis, City of Hope, Taipai Medical University and National Health Research Institutes in Taiwan have discovered how a drug that deprives the cells of a key amino acid specifically kills cancer cells.

12 Aug 2014

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.

12 Aug 2014

Research sheds light on role of hepatic mTORC1 in whole body physiology

The protein mTOR is a central controller of growth and metabolism. Deregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

CRI researchers identify gene linked to several childhood cancers

Researchers at the Children-s Medical Center Research Institute at UT Southwestern have identified a gene that contributes to the development of several childhood cancers, in a study conducted with mice designed to model the cancers.

11 Aug 2014

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

11 Aug 2014

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.

8 Aug 2014

Scientists solve key mystery in cancer research

A chance meeting between two leading UK and US scientists could have finally helped solve a key mystery in cancer research.

8 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Cancer cells that break away from tumors may prefer to settle into soft bed

Cancer cells that break away from tumors to go looking for a new home may prefer to settle into a soft bed, according to new findings from researchers at the University of Illinois.

8 Aug 2014